226 related articles for article (PubMed ID: 23421467)
1. Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells.
Takeuchi A; Yamamoto Y; Munesue S; Harashima A; Watanabe T; Yonekura H; Yamamoto H; Tsuchiya H
Cancer Sci; 2013 Jun; 104(6):740-9. PubMed ID: 23421467
[TBL] [Abstract][Full Text] [Related]
2. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
Riuzzi F; Sorci G; Donato R
J Biol Chem; 2006 Mar; 281(12):8242-53. PubMed ID: 16407300
[TBL] [Abstract][Full Text] [Related]
3. The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin.
Zenerino C; Nuzzo AM; Giuffrida D; Biolcati M; Zicari A; Todros T; Rolfo A
Molecules; 2017 Nov; 22(11):. PubMed ID: 29149067
[TBL] [Abstract][Full Text] [Related]
4. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line.
Choi J; Lee MK; Oh KH; Kim YS; Choi HY; Baek SK; Jung KY; Woo JS; Lee SH; Kwon SY
Tumori; 2011; 97(2):196-202. PubMed ID: 21617715
[TBL] [Abstract][Full Text] [Related]
5. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.
Arumugam T; Ramachandran V; Gomez SB; Schmidt AM; Logsdon CD
Clin Cancer Res; 2012 Aug; 18(16):4356-64. PubMed ID: 22718861
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
[TBL] [Abstract][Full Text] [Related]
7. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L; Zhong K; Sun Z; Wu G; Ding G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):11-22. PubMed ID: 21947243
[TBL] [Abstract][Full Text] [Related]
8. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines.
Chen RC; Yi PP; Zhou RR; Xiao MF; Huang ZB; Tang DL; Huang Y; Fan XG
Mol Cell Biochem; 2014 May; 390(1-2):271-80. PubMed ID: 24510323
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.
Ren L; Lou Y; Sun M
Bioengineered; 2021 Dec; 12(1):5985-5995. PubMed ID: 34477479
[TBL] [Abstract][Full Text] [Related]
10. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.
Riuzzi F; Sorci G; Donato R
Am J Pathol; 2007 Sep; 171(3):947-61. PubMed ID: 17640970
[TBL] [Abstract][Full Text] [Related]
11. HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
Amornsupak K; Thongchot S; Thinyakul C; Box C; Hedayat S; Thuwajit P; Eccles SA; Thuwajit C
BMC Cancer; 2022 May; 22(1):578. PubMed ID: 35610613
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.
Bassi R; Giussani P; Anelli V; Colleoni T; Pedrazzi M; Patrone M; Viani P; Sparatore B; Melloni E; Riboni L
J Neurooncol; 2008 Mar; 87(1):23-33. PubMed ID: 17975708
[TBL] [Abstract][Full Text] [Related]
13. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
Rao NV; Argyle B; Xu X; Reynolds PR; Walenga JM; Prechel M; Prestwich GD; MacArthur RB; Walters BB; Hoidal JR; Kennedy TP
Am J Physiol Cell Physiol; 2010 Jul; 299(1):C97-110. PubMed ID: 20375277
[TBL] [Abstract][Full Text] [Related]
14. Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway.
Huang M; Geng Y; Deng Q; Li R; Shao X; Zhang Z; Xu W; Wu Y; Ma Q
Int J Oncol; 2018 Oct; 53(4):1481-1492. PubMed ID: 30066846
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-products.
Sparatore B; Pedrazzi M; Passalacqua M; Gaggero D; Patrone M; Pontremoli S; Melloni E
Biochem J; 2002 May; 363(Pt 3):529-35. PubMed ID: 11964153
[TBL] [Abstract][Full Text] [Related]
16. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site.
Ishihara K; Tsutsumi K; Kawane S; Nakajima M; Kasaoka T
FEBS Lett; 2003 Aug; 550(1-3):107-13. PubMed ID: 12935895
[TBL] [Abstract][Full Text] [Related]
17. Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding.
Liu R; Mori S; Wake H; Zhang J; Liu K; Izushi Y; Takahashi HK; Peng B; Nishibori M
Acta Med Okayama; 2009 Aug; 63(4):203-11. PubMed ID: 19727205
[TBL] [Abstract][Full Text] [Related]
18. Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE.
Jing R; Chen W; Wang H; Ju S; Cong H; Sun B; Jin Q; Chu S; Xu L; Cui M
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(9):G719-29. PubMed ID: 26316588
[TBL] [Abstract][Full Text] [Related]
19. High-Mobility Group Box 1 (HMGB1) Induces Migration of Endothelial Progenitor Cell via Receptor for Advanced Glycation End-Products (RAGE)-Dependent PI3K/Akt/eNOS Signaling Pathway.
Zhang Y; You B; Liu X; Chen J; Peng Y; Yuan Z
Med Sci Monit; 2019 Aug; 25():6462-6473. PubMed ID: 31461437
[TBL] [Abstract][Full Text] [Related]
20. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.
Huttunen HJ; Fages C; Rauvala H
J Biol Chem; 1999 Jul; 274(28):19919-24. PubMed ID: 10391939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
